<DOC>
	<DOC>NCT00528619</DOC>
	<brief_summary>This study will assess the maximum tolerated dose, overall safety and antitumor activity of SU011248 in combination with pemetrexed, pemetrexed and cisplatin or pemetrexed and carboplatin in patients with advanced solid tumors.</brief_summary>
	<brief_title>A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Patients with a diagnosis of a solid cancer which is not responsive to standard therapy or for which no standard therapy exists. Patient has a good performance status (ECOG 0 or 1). Prior treatment with either pemetrexed or SU011248. Coughing up blood within 4 weeks before starting study treatment (small amounts okay). Hypertension that cannot be controlled by medications.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Solid tumor malignancy</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>sunitinib</keyword>
	<keyword>pemetrexed</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Mesothelioma</keyword>
</DOC>